Tumor-bearing mice treated with anti-PVRIG mAb showed lower expression of inhibitory receptors CD96 and PD-1 (Fig. 5a) and higher expression of activating receptor NKG2D and cytotoxic molecule TRAIL on tumor-infiltrating NK cells (Fig. 5b). Here, CD96 is linked to neoplasm.